1. Compared to usual care, fewer patients in the tocilizumab group died within 28 days of randomization. 2. Patients allocated ...
1. Compared to usual care, fewer patients in the tocilizumab group died within 28 days of randomization. 2. Patients allocated ...
1. Tocilizumab reduced the need for mechanical ventilation and lowered death outcomes in patients infected with severe acute respiratory syndrome ...
1. Tocilizumab reduced the need for mechanical ventilation and lowered death outcomes in patients infected with severe acute respiratory syndrome ...
1. Treatment with tocilizumab and sarilumab increased the number of days without respiratory or cardiovascular organ support in patients with ...
1. Among patients categorized as B-cell poor group via RNA sequencing, tocilizumab had a significantly higher response rate than rituximab. ...
1. Tocilizumab was not superior to standard care after 15 days, for COVID-19 patients in serious condition. 2. Patients given ...
1. Among patients categorized as B-cell poor group via RNA sequencing, tocilizumab had a significantly higher response rate than rituximab. ...
1. Hydroxychloroquine use in hospitalized and tocilizumab use in ICU lab-positive COVID-19 patients were not been associated with decreased death. ...
Tumour necrosis factor (TNF) alpha inhibitors have greatly improved disease control and quality of life in patients affected by rheumatoid ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.